ViaGen Pets
US commercial pet cloning — Texas, 2015-
Successor To Genetic Savings & Clone (founded 1997, dissolved 2006); re-launched commercial pet cloning 2015 from inherited mechanics + customer base.
600+ cloned dogs + 400+ cloned cats by 2024. ~25% global pet-cloning market share. Per-dog cost ~$50,000. Operates entirely outside Western academic ethical moratoria — pure commercial-veterinary jurisdiction.
Engine Framing: cap-table-adjacent to Longevity Industrial Complex operator-class capital — same mortality-anxiety conversion mechanism (immortality drives) applied to companion-animal layer. Public perception treats pet cloning as fringe novelty; market reality is industrialized elite-genetic-replication assembly line.
Also in Cloning Substrate Post-Dolly
Sooam Biotech Research FoundationSubstrate-continuation commercial node — Seoul, 20Sinogene BiotechnologyChinese commercial pet cloning — Beijing, 2017-Trans Ova GeneticsIndustrial-agricultural SCNT — Iowa, 2002-Mitalipov OHSU Center for Embryonic Cell and Gene TherapyWestern academic human-SCNT + germline node — OregHe Jiankui — Post-Prison Disclosure-Window ProbeCRISPR-babies operator → Hainan post-prison continCAS Shanghai Primate SCNT PipelineState-coordinated primate-cloning substrate monopoColossal BiosciencesOperator-class capital de-extinction substrate — T